Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 167.34M +81.4% |
| Revenue (ttm) | 1.78M |
| Net Income | -68.36M |
| EPS | -0.69 |
| Shares Out | 136.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,485,677 |
| Open | 1.260 |
| Previous Close | 1.230 |
| Day's Range | 1.215 - 1.280 |
| 52-Week Range | 1.000 - 3.060 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 6.33 (+414.63%) |
| Earnings Date | May 13, 2026 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MIST stock is "Buy." The 12-month stock price target is $6.33, which is an increase of 414.63% from the latest price.
News
Milestone Pharmaceuticals Slides: Corporate presentation
Milestone Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Milestone Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
CARDAMYST's launch addresses a significant unmet need in PSVT, with rapid adoption among prescribers and positive early feedback. Commercial strategy focuses on expanding payer coverage and piloting patient activation, while a phase III AFib trial and a real-world patient registry are set to drive future growth.
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovativ...
Milestone Pharmaceuticals files $300M mixed securities shelf
17:30 EDT Milestone Pharmaceuticals (MIST) files $300M mixed securities shelf
Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c
Reports Q1 revenue $238,000, consensus $37.64M. “We’re excited to report on our first quarter of sales for CARDAMYST for paroxysmal supraventricular tachycardia, or PSVT. Healthcare professionals’ ini...
Milestone Pharmaceuticals Earnings Call Transcript: Q1 2026
First quarter post-launch saw strong initial uptake of CARDEMYST, with 600 prescriptions written by over 400 providers and positive feedback from patients and prescribers. Cash position is robust, supporting operations into 2027, and payer coverage is expanding, highlighted by Express Scripts formulary inclusion.
Milestone Pharmaceuticals Quarterly report: Q1 2026
Milestone Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 13, 2026.
Milestone Pharmaceuticals Earnings release: Q1 2026
Milestone Pharmaceuticals released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Milestone Pharmaceuticals Registration statement: Registration filing
Milestone Pharmaceuticals filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative...
Milestone Pharmaceuticals Slides: Corporate presentation
Milestone Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
Milestone Pharmaceuticals Proxy statement: Proxy filing
Milestone Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Milestone Pharmaceuticals Proxy statement: Proxy filing
Milestone Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Milestone Pharmaceuticals Slides: Corporate presentation
Milestone Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Milestone Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
CARDAMYST launched as the first new PSVT treatment in decades, offering rapid, at-home relief and strong clinical data. The company is targeting 10,000 key providers with 60 sales reps, secured initial payer coverage, and is advancing a phase III trial for AFib-RVR, supported by $200M in cash and a clear path to break-even.
Milestone Pharmaceuticals provides details on RESET-PSVT trial
Milestone Pharmaceuticals (MIST) announced details on RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry intended to generate real-world evidence on the use of Cardamyst n...
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium Registry Study Design Presented at the Preventive Cardiovascular Nurses Associ...
Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James
Raymond James last night initiated coverage of Milestone Pharmaceuticals (MIST) with a Strong Buy rating and $6 price target At current share levels, the market is only assigning less than…
Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James
Raymond James analyst Tiago Fauth initiated coverage of Milestone Pharmaceuticals (MIST) with a Strong Buy rating and $6 price target
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovati...
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, i...
Milestone Pharmaceuticals announces availability of Cardamyst on Express Scripts
Milestone Pharmaceuticals (MIST) announced that Express Scripts has added Cardamyst nasal spray to its commercial national formularies, effective March 2.
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025
FDA approval and U.S. launch of CARDAMYST marked a pivotal year, with strong initial prescription activity and a robust $200 million cash position supporting operations into late 2027. Early payer coverage is limited, but commercial and Medicare access are expected to expand in 2026–2027.